Is KalVista Pharmaceuticals, Inc. (KALV) a Buy, Sell, or Hold?
NASDAQ : KALV
KalVista Pharmaceuticals, Inc.
$27 USD
$0 (0.0%)
- Volume
- 4.26M
- Average Volume
- 3.54M
- Market Capitalization
- $1.44B
- P/E Ratio
- -8.36
- Dividend Yield
- 0.00%
- Price Target
- $27.00
- Year High
- $27.00
- Year Low
- $9.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.58
Company Overview
NASDAQ
Benjamin L. Palleiko
Biotechnology
Healthcare
KALV
275
US
USD
Liquidity Metrics
-104.83
5.58
5.52
4.00
0.00
Sales & Valuation
$73.62M
12.40
-503.31
-25.42
-1.12
Profitability
-$3.23
-$164.29M
-119.44%
-121.84%
-1057.44%
-41.28%
P/E Metrics
-8.36
-0.56
-0.56
Analyst Price Target & Rating
$27.00
$27.00
$27.00
0/5
13 Analysts
0.00%
Poll Results
About KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA. ...
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
2026-06-11 08:41:00
PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercialization of therapies for rare and ultra-rare conditions. With the completion of the transac.
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-04 13:01:16
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
2026-05-31 11:48:43
This clinical-stage biotech focused on rare diseases reported a notable insider sale amid a year of strong stock performance.
2026-05-28 08:00:00
[url="]KalVista Pharmaceuticals[/url], Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged
2026-05-28 07:00:00
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben Palleiko, Chief Executive Officer of KalVista. “Currentl.
2026-05-19 15:00:00
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
2026-05-19 14:11:00
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequ.
2026-05-01 12:30:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are.
Frequently Asked Questions
-
What is the current KalVista Pharmaceuticals, Inc. (KALV) stock price?
-
KalVista Pharmaceuticals, Inc.(NASDAQ:KALV) stock price is $27 in the last trading session. During the trading session, KALV stock reached the peak price of $27 while $9.83 was the lowest point it dropped to. The percentage change in KALV stock occurred in the recent session was 0.0% while the dollar amount for the price change in KALV stock was $0.
-
KALV's industry and sector of operation?
-
The NASDAQ listed KALV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KALV?
-
Benjamin L. Palleiko | Chief Executive Officer & Director
Brian Krex | General Counsel
Rachel Morten | Senior Vice President of Regulatory Affairs & QA
Jarrod Aldom | Vice President of Corporate Communications
Christopher Yea | Chief Development Officer -
How many employees does KALV have?
-
Number of KALV employees currently stands at 275. KALV operates from 200 Crossing Boulevard, Framingham, MA 01702, US.
-
Link for KALV official website?
-
Official Website of KALV is: https://www.kalvista.com
-
How do I contact KALV?
-
KALV could be contacted at phone #857 999 0075 and can also be accessed through its website. KALV operates from 200 Crossing Boulevard, Framingham, MA 01702, US.
-
How many shares of KALV are traded daily?
-
The average number of KALV shares traded daily for last 3 months was 3.54M.
-
What is the market cap of KALV currently?
-
The market value of KALV currently stands at $1.44B with its latest stock price at $27